Wed. 7 Feb 2024, 9:18am ET
Benzinga
Biotech, News, General
- ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer's Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.
- Mild Alzheimer's Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24.
- Oral Simufilam Safe, Well-Tolerated.